Telehealth Update: DEA Extends Flexibility in Prescribing Controlled Substances via Telehealth Through 2024

On October 10, 2023, the Drug Enforcement Administration (DEA) published another temporary rule extending the COVID-era telemedicine flexibilities that allow physicians and other prescribers to prescribe controlled substances without an in-person evaluation. With just over a month to go before the expiration of the first set of flexibilities, the DEA announced that the telemedicine flexibilities, which have been in place since March 2020, will be extended through the end of 2024 in order to…
By: Mintz – Health Care Viewpoints
Previous Story

FDA Seeks to Increase Regulatory Oversight of Laboratory Developed Tests

Next Story

Circuits in Session: Addendum and Elaboration of the Appellate Court Judge Experiment